{"@context": "https://schema.org", "@graph": [{"@type": "MedicalWebPage", "@id": "https://www.eden.health/learn/retatrutide", "url": "https://www.eden.health/learn/retatrutide", "name": "Retatrutide: what it is, what research shows, and whether it's available", "description": "As of October 27, 2026, retatrutide is an investigational once-weekly injection that activates GIP, GLP-1, and glucagon receptors. It is not FDA-approved or commercially available, Eden does not offer it, and the FDA says it cannot be used in compounding under federal law. This U.S.-focused guide summarizes the evidence and what remains unknown.", "inLanguage": "en-US", "dateModified": "2026-10-27T12:00:00.000Z", "publisher": {"@type": "Organization", "name": "Eden", "url": "https://www.eden.health/"}, "citation": ["https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss", "https://www.lilly.com/news/stories/what-to-know-about-retatrutide", "https://www.nejm.org/doi/full/10.1056/NEJMoa2604169", "https://clinicaltrials.gov/study/NCT05929066", "https://pubmed.ncbi.nlm.nih.gov/42810372/", "https://clinicaltrials.gov/study/NCT06662383", "https://clinicaltrials.gov/study/NCT07629401", "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s015lbl.pdf", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s013lbl.pdf", "https://doi.org/10.1056/NEJMoa2301972", "https://doi.org/10.1038/s41591-024-03018-2", "https://pubmed.ncbi.nlm.nih.gov/41090431/"]}, {"@type": "FAQPage", "mainEntity": [{"@type": "Question", "name": "Is retatrutide FDA-approved?", "acceptedAnswer": {"@type": "Answer", "text": "No. As of October 27, 2026, retatrutide remains investigational and is not FDA-approved."}}, {"@type": "Question", "name": "Does Eden offer retatrutide?", "acceptedAnswer": {"@type": "Answer", "text": "No. Eden does not offer, prescribe, compound, or sell retatrutide. This page is educational and does not advertise access to the investigational medicine."}}, {"@type": "Question", "name": "Can a compounding pharmacy make retatrutide?", "acceptedAnswer": {"@type": "Answer", "text": "No. The FDA states that retatrutide cannot be used in compounding under federal law. Products marketed as “compounded retatrutide” or “research use only” may be unapproved, mislabeled, or unsafe."}}, {"@type": "Question", "name": "Where can someone get retatrutide?", "acceptedAnswer": {"@type": "Answer", "text": "Retatrutide is not commercially available. Access may be possible only through an authorized clinical trial or the narrow expanded-access protocol listed on ClinicalTrials.gov. Neither is an Eden program."}}, {"@type": "Question", "name": "Is retatrutide a “GLP-3” medicine?", "acceptedAnswer": {"@type": "Answer", "text": "No. “GLP-3” is informal shorthand, not a recognized scientific class. Retatrutide is more accurately described as an investigational GIP, GLP-1, and glucagon triple-receptor agonist."}}, {"@type": "Question", "name": "What side effects have trials reported?", "acceptedAnswer": {"@type": "Answer", "text": "Gastrointestinal effects such as nausea and diarrhea were among the most commonly reported adverse events. Retatrutide does not yet have FDA-approved prescribing information, so trial protocols should not be treated as a personal treatment guide."}}, {"@type": "Question", "name": "Is retatrutide better than tirzepatide?", "acceptedAnswer": {"@type": "Answer", "text": "That has not been established. Retatrutide and tirzepatide act on different receptor combinations, but separate placebo-controlled studies cannot establish a head-to-head winner. The direct TRIUMPH-5 study is active, and no results had been posted when this page was fact-checked."}}, {"@type": "Question", "name": "When will retatrutide be available?", "acceptedAnswer": {"@type": "Answer", "text": "There is no confirmed approval or public-launch date. Lilly has said it plans a U.S. regulatory submission in the first quarter of 2027. A planned filing does not guarantee approval or establish timing."}}, {"@type": "Question", "name": "How much will retatrutide cost?", "acceptedAnswer": {"@type": "Answer", "text": "No approved commercial price exists because retatrutide is not approved for sale. Any price advertised today is not the price of an FDA-approved retatrutide product."}}, {"@type": "Question", "name": "Can someone join a retatrutide clinical trial?", "acceptedAnswer": {"@type": "Answer", "text": "Possibly, if a registered study is recruiting and the person meets its protocol. Review current studies on ClinicalTrials.gov’s retatrutide search; a listing does not guarantee that a study is open or available nearby."}}, {"@type": "Question", "name": "What did earlier retatrutide studies find?", "acceptedAnswer": {"@type": "Answer", "text": "A 48-week Phase 2 obesity trial reported 24.2% mean weight reduction at the 12 mg dose versus 2.1% with placebo. A separate 48-week MASLD substudy reported large relative reductions in liver fat at week 24 in the 8 mg and 12 mg groups. These population-specific findings are not approved indications or individual predictions."}}]}, {"@type": "BreadcrumbList", "itemListElement": [{"@type": "ListItem", "position": 1, "name": "Learn", "item": "https://www.eden.health/learn"}, {"@type": "ListItem", "position": 2, "name": "Medications", "item": "https://www.eden.health/learn-topics/medications"}, {"@type": "ListItem", "position": 3, "name": "Retatrutide", "item": "https://www.eden.health/learn/retatrutide"}]}]}
Retatrutide: what it is, what research shows, and whether it's available
As of October 27, 2026, retatrutide is an investigational once-weekly injection that activates GIP, GLP-1, and glucagon receptors. It is not FDA-approved or commercially available, Eden does not offer it, and the FDA says it cannot be used in compounding under federal law. This U.S.-focused guide summarizes the evidence and what remains unknown.
Retatrutide is investigational. It is not an Eden treatment.
As of October 27, 2026, retatrutide is not FDA-approved or commercially available. The FDA says retatrutide cannot be used in compounding under federal law. Products sold online as “retatrutide” may be unapproved, mislabeled, or unsafe. [1]
Get AI summary
Current status
Retatrutide at a glance
These are the basic facts we can currently verify.
Verified status as of October 27, 2026
Question
Current answer
Primary support
What is it?
An investigational GIP, GLP-1, and glucagon triple-receptor agonist
A single molecule designed to act on three receptors
Retatrutide is designed to activate receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Researchers are studying how this combination affects appetite, energy use, blood sugar, and body weight. [2]
The mechanism alone does not establish that retatrutide is safer, more effective, or appropriate for a particular person. Those questions depend on completed studies, regulatory review, and, if approved, the final prescribing information.
What the research shows
Phase 3 trials reported substantial average weight change in defined study populations
These are controlled-trial group averages tied to specific populations, doses, time periods, and analysis methods. They are not individual predictions, approved claims, or proof that retatrutide is better than another medicine.
TRIUMPH-1 · Phase 3
Peer reviewed
Adults with obesity without type 2 diabetes
Randomized in paper
2,339*
Duration
80 weeks
Comparator
Placebo
Mean change in body weight at 80 weeks
Assigned group
Mean change
Retatrutide 4 mg
−17.6%
Retatrutide 9 mg
−23.7%
Retatrutide 12 mg
−25.0%
Placebo
−3.9%
Sources: NEJM publication [3] and ClinicalTrials.gov [4]. *The paper reports 2,339 randomized participants; the registry currently lists 2,335 actual enrollment. The denominator must be reconciled with medical review before publication.
TRIUMPH-2 · Phase 3
Peer reviewed
Adults with obesity or overweight and type 2 diabetes
Retatrutide produced greater average weight change than placebo in the reported study populations.
The observed result varied by assigned dose and patient population.
Gastrointestinal events were among the most commonly reported adverse events.
What remains unknown
The trials do not settle approval, access, price, or head-to-head superiority.
Whether or when the FDA will approve retatrutide
The final indications, doses, warnings, or contraindications
Public launch timing, price, insurance coverage, or supply
How it compares directly with tirzepatide; no TRIUMPH-5 results were posted at review [6]
Long-term safety and effectiveness outside controlled trials
Earlier clinical evidence
Phase 2 studies help explain the development path, but they do not create an approved use.
These earlier studies add context to the development program. Their findings remain tied to the studied populations, doses, time points, and primary publications.
Phase 2 obesity trial · 2023
338 adults · 48 weeks
At 12 mg, the study reported a mean body-weight change of −24.2%, compared with −2.1% for placebo. The result belongs to this randomized trial and does not predict an individual outcome.
At week 24, the 8 mg and 12 mg groups had 81.4% and 82.4% relative reductions in hepatic lipid content, compared with a 0.3% increase for placebo. This was a population-specific research finding, not an FDA-approved liver-disease indication.
Retatrutide differs from semaglutide and tirzepatide, but “more receptors” does not mean “better.”
The clean comparison is what each molecule activates and whether products containing it have FDA approval—not cross-trial promises about which one will work best.
Molecule
Receptors
U.S. status
What we can conclude
Semaglutide
GLP-1
FDA-approved branded products exist for specific uses [9]
Different molecule and evidence base
Tirzepatide
GIP + GLP-1
FDA-approved branded products exist for specific uses [10]
Different molecule and evidence base
Retatrutide
GIP + GLP-1 + glucagon
Investigational; not FDA-approved
No completed head-to-head superiority claim
Results from separate trials should not be treated as if the medicines were compared directly under the same protocol.
Safety and access
Retatrutide does not have FDA-approved prescribing information
Gastrointestinal effects, including nausea and diarrhea, were among the most commonly reported adverse events in Phase 3. Some participants discontinued treatment because of adverse events. Clinical-trial protocols should not be used as personal dosing, titration, contraindication, or treatment instructions.
Commercial access
Not available
There is no approved retatrutide product, price, prescription, or legitimate retail pathway.
Research access
Protocol dependent
Some people may qualify for an authorized clinical trial. ClinicalTrials.gov also lists a narrow single-patient expanded-access protocol; that is not routine consumer access. [7]
Online products
Avoid them
The FDA warns consumers about unapproved products sold as retatrutide or labeled “research use only.” [1]
Common questions
Direct answers
Each answer starts with the conclusion, then gives the limitation or source context you need.
Is retatrutide FDA-approved?
No. As of October 27, 2026, retatrutide remains investigational and is not FDA-approved.
Does Eden offer retatrutide?
No. Eden does not offer, prescribe, compound, or sell retatrutide. This page is educational and does not advertise access to the investigational medicine.
Can a compounding pharmacy make retatrutide?
No. The FDA states that retatrutide cannot be used in compounding under federal law. Products marketed as “compounded retatrutide” or “research use only” may be unapproved, mislabeled, or unsafe.
Where can someone get retatrutide?
Retatrutide is not commercially available. Access may be possible only through an authorized clinical trial or the narrow expanded-access protocol listed on ClinicalTrials.gov. Neither is an Eden program.
Is retatrutide a “GLP-3” medicine?
No. “GLP-3” is informal shorthand, not a recognized scientific class. Retatrutide is more accurately described as an investigational GIP, GLP-1, and glucagon triple-receptor agonist.
What side effects have trials reported?
Gastrointestinal effects such as nausea and diarrhea were among the most commonly reported adverse events. Retatrutide does not yet have FDA-approved prescribing information, so trial protocols should not be treated as a personal treatment guide.
Is retatrutide better than tirzepatide?
That has not been established. Retatrutide and tirzepatide act on different receptor combinations, but separate placebo-controlled studies cannot establish a head-to-head winner. The direct TRIUMPH-5 study is active, and no results had been posted when this page was fact-checked.
When will retatrutide be available?
There is no confirmed approval or public-launch date. Lilly has said it plans a U.S. regulatory submission in the first quarter of 2027. A planned filing does not guarantee approval or establish timing. [8]
How much will retatrutide cost?
No approved commercial price exists because retatrutide is not approved for sale. Any price advertised today is not the price of an FDA-approved retatrutide product.
Can someone join a retatrutide clinical trial?
Possibly, if a registered study is recruiting and the person meets its protocol. Review current studies on ClinicalTrials.gov’s retatrutide search; a listing does not guarantee that a study is open or available nearby.
What did earlier retatrutide studies find?
A 48-week Phase 2 obesity trial reported 24.2% mean weight reduction at the 12 mg dose versus 2.1% with placebo. A separate 48-week MASLD substudy reported large relative reductions in liver fat at week 24 in the 8 mg and 12 mg groups. These population-specific findings are not approved indications or individual predictions. [11][12]
Source transparency
Primary sources behind this page
Material statements are tied to regulators, peer-reviewed research, registered trials, or the developer's current status disclosures. Affiliate summaries are never used as clinical or regulatory proof.
Educational information only. This page is not medical advice and does not replace evaluation by a licensed healthcare professional. Retatrutide is investigational and is not offered by Eden.
Explore treatment options with Eden
See which treatments are available, how they work, and what they cost. If one looks right for you, a licensed clinician reviews your online intake.
